All patients with atheromatous renovascular disease (ARVD) should be considered for treatment with renin–angiotensin blockade (RAB) unless absolutely contraindicated, state the authors of a recent study. Chrysochou et al. analyzed data from 621 individuals with ARVD and found that RAB was well tolerated in most patients receiving it, even in 78% of those with bilateral renal artery stenosis of ≥60% or occlusion. Patients receiving RAB were less likely to die over the 10-year study period than those not receiving such treatment.
ORIGINAL RESEARCH PAPER
Chrysochou, C. et al. Dispelling the myth: the use of renin–angiotensin blockade in atheromatous renovascular disease. Nephrol. Dial. Transplant. doi:10.1093/ndt/gfr496
Rights and permissions
About this article
Cite this article
Renin–angiotensin blockade in ARVD. Nat Rev Nephrol 7, 677 (2011). https://doi.org/10.1038/nrneph.2011.164
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2011.164
